Q2 Earnings Estimate for Hologic Issued By Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of Hologic in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will earn $1.02 per share for the quarter, down from their previous estimate of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic’s Q2 2026 earnings at $1.15 EPS, Q3 2026 earnings at $1.18 EPS, Q4 2026 earnings at $1.19 EPS and FY2026 earnings at $4.65 EPS.

HOLX has been the subject of a number of other reports. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Raymond James raised their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Evercore ISI upped their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Stock Up 1.2 %

Shares of NASDAQ:HOLX opened at $71.19 on Wednesday. The company has a 50 day moving average of $74.30 and a two-hundred day moving average of $78.31. Hologic has a 52-week low of $68.61 and a 52-week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $16.07 billion, a price-to-earnings ratio of 21.38, a price-to-earnings-growth ratio of 2.38 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.89 earnings per share.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Federated Hermes Inc. acquired a new position in shares of Hologic during the second quarter valued at $246,000. ProShare Advisors LLC lifted its position in Hologic by 6.0% in the 2nd quarter. ProShare Advisors LLC now owns 39,529 shares of the medical equipment provider’s stock valued at $2,935,000 after purchasing an additional 2,225 shares during the last quarter. Frank Rimerman Advisors LLC acquired a new position in Hologic during the 2nd quarter valued at about $371,000. 1832 Asset Management L.P. grew its position in Hologic by 3.4% in the 2nd quarter. 1832 Asset Management L.P. now owns 28,352 shares of the medical equipment provider’s stock worth $2,105,000 after purchasing an additional 935 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its stake in shares of Hologic by 92.5% in the second quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider’s stock valued at $650,000 after purchasing an additional 4,208 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.